We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Fresenius Kabi to Acquire Fenwal Holdings

By LabMedica International staff writers
Posted on 02 Aug 2012
Print article
Fresenius Kabi (Bad Homburg, Germany) will acquire Fenwal Holdings, Inc., (Lake Zurich, IL, USA) a US-based provider of transfusion technology products for blood collection, separation, and processing from TPG (formally Texas Pacific Group) and Maverick Capital.


The acquisition marks another major step in Fresenius Kabi's previous statement that expanding its medical devices/transfusion technology segment is a priority. Fresenius Kabi will now become a global leader in transfusion technology.

The two companies' business activities complement each other: Fenwal holds a stable position in the market for automated blood collection devices, while Fresenius Kabi is a major supplier of blood bags and filters used for manual blood collection. Combining the two businesses will lead to a comprehensive product portfolio in transfusion medicine.

In addition, the acquisition will enhance Fresenius Kabi's geographical presence. Fenwal, headquartered in Lake Zurich (IL, USA) generates more than half its sales in the United States, where its infrastructure will serve as a platform for further growth opportunities for Fresenius Kabi. Conversely, Fresenius Kabi's international network will expand Fenwal's global product reach. Significant potential for revenue and cost synergies will be created.

In 2011, Fenwal had sales of USD 614 million with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of USD 90 million. The company runs a state-of-the-art R&D center and operates five manufacturing facilities.

Approximately 92 million whole blood donations are collected annually around the world. The transfusion technology market is mainly driven by demographic developments and the growing demand for products for automated blood component processing. In addition, the increasing demand in emerging markets will lead to further growth in this product segment.

Financial terms were not disclosed. The transaction will be financed initially from existing funds, whereas the enterprise value does not exceed the proceeds of the May 2012 capital increase.

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.

Related Links:

Fresenius Kabi
Fenwal Holdings, Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.